Immune checkpoints as therapeutic targets in autoimmunity
Antibodies that block the immune checkpoint receptors PD1 and CTLA4 have revolutionized the treatment of melanoma and several other cancers, but in the process, a new class of drug side effect has emerged-immune related adverse events. The observation that therapeutic blockade of these inhibitory re...
Main Authors: | Paluch, C, Santos, A, Anzilotti, C, Cornall, R, Davis, S |
---|---|
格式: | Journal article |
语言: | English |
出版: |
Frontiers Media
2018
|
相似书籍
-
Immune Checkpoints as Therapeutic Targets in Autoimmunity
由: Christopher Paluch, et al.
出版: (2018-10-01) -
Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
由: Yujia Zhai, et al.
出版: (2021-04-01) -
Combination CD200R/PD-1 blockade in a humanised mouse model
由: Fellermeyer, M, et al.
出版: (2023) -
Manipulating immune checkpoint signalling pathways with antibodies
由: Paluch, C
出版: (2019) -
Dermatological Autoimmune Considerations of Immune Checkpoint Therapy
由: Lauren S. Fane, et al.
出版: (2022-09-01)